Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer
PurposeHost immunity influences the impact of cancer therapy but the effect of immune status in radioiodine (RAI)-treated differentiated thyroid cancer (DTC) remains obscure. Here we investigated indoleamine 2,3-dioxygenase (IDO) activity as a biomarker of response to RAI in patients with distant me...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.871792/full |
| _version_ | 1818097281275002880 |
|---|---|
| author | Liang Shi Rui Duan Rui Duan Qiong Jia Wenyu Wu Jianming Zhou Shaohua Li Hao Zhang Xue Xue |
| author_facet | Liang Shi Rui Duan Rui Duan Qiong Jia Wenyu Wu Jianming Zhou Shaohua Li Hao Zhang Xue Xue |
| author_sort | Liang Shi |
| collection | DOAJ |
| description | PurposeHost immunity influences the impact of cancer therapy but the effect of immune status in radioiodine (RAI)-treated differentiated thyroid cancer (DTC) remains obscure. Here we investigated indoleamine 2,3-dioxygenase (IDO) activity as a biomarker of response to RAI in patients with distant metastatic DTC (dmDTC).MethodsPatients with dmDTC receiving RAI were evaluated for serum IDO activity (kynurenine and kynurenine:tryptophan ratio) at baseline and 3 months after RAI. The optimal cut-off value for these biomarkers to predict response was established by receiver operating characteristic analysis. The relationship between disease outcomes, overall survival (OS) and progression-free survival (PFS), and IDO activity levels was studied.ResultsHigher baseline kynurenine:tryptophan ratio (>2.46) was correlated with poorer RAI response as well as shorter median PFS (45 mo versus not reached, p=0.002) and OS (78 mo versus not reached, p=0.035). High baseline kynurenine:tryptophan ratio was also correlated with a reduced number of tumor-infiltrating lymphocytes. Higher post/pre-kynurenine ratio (>1.69) was associated with survival endpoints: shorter median PFS (48 mo versus not reached, p=0.002) and OS (68 mo versus not reached, p=0.010). Favorable baseline and favorable change corresponded with better PFS and OS.ConclusionsOur results suggest that RAI also alters IDO activity in dmDTC patients. IDO activity could predict progression and survival outcomes for advanced dmDTC patients. Serum IDO biomarker levels could be used to select dmDTC likely to benefit from RAI therapy, although further studies are necessary. |
| first_indexed | 2024-12-10T23:18:01Z |
| format | Article |
| id | doaj.art-d0e8306013fb43bdadd2ec5efec29e89 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-10T23:18:01Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d0e8306013fb43bdadd2ec5efec29e892022-12-22T01:29:48ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.871792871792Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid CancerLiang Shi0Rui Duan1Rui Duan2Qiong Jia3Wenyu Wu4Jianming Zhou5Shaohua Li6Hao Zhang7Xue Xue8Department of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Neurology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Nuclear Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaDepartment of Emergency, Affiliated Hospital of Jiangsu University, Zhenjiang, ChinaDepartment of Nuclear Medicine, Nanjing First Hospital, Nanjing Medical University, Nanjing, ChinaPurposeHost immunity influences the impact of cancer therapy but the effect of immune status in radioiodine (RAI)-treated differentiated thyroid cancer (DTC) remains obscure. Here we investigated indoleamine 2,3-dioxygenase (IDO) activity as a biomarker of response to RAI in patients with distant metastatic DTC (dmDTC).MethodsPatients with dmDTC receiving RAI were evaluated for serum IDO activity (kynurenine and kynurenine:tryptophan ratio) at baseline and 3 months after RAI. The optimal cut-off value for these biomarkers to predict response was established by receiver operating characteristic analysis. The relationship between disease outcomes, overall survival (OS) and progression-free survival (PFS), and IDO activity levels was studied.ResultsHigher baseline kynurenine:tryptophan ratio (>2.46) was correlated with poorer RAI response as well as shorter median PFS (45 mo versus not reached, p=0.002) and OS (78 mo versus not reached, p=0.035). High baseline kynurenine:tryptophan ratio was also correlated with a reduced number of tumor-infiltrating lymphocytes. Higher post/pre-kynurenine ratio (>1.69) was associated with survival endpoints: shorter median PFS (48 mo versus not reached, p=0.002) and OS (68 mo versus not reached, p=0.010). Favorable baseline and favorable change corresponded with better PFS and OS.ConclusionsOur results suggest that RAI also alters IDO activity in dmDTC patients. IDO activity could predict progression and survival outcomes for advanced dmDTC patients. Serum IDO biomarker levels could be used to select dmDTC likely to benefit from RAI therapy, although further studies are necessary.https://www.frontiersin.org/articles/10.3389/fonc.2022.871792/fulldifferentiated thyroid cancerradioiodineindoleamine 23-dioxygenase (IDO)immune suppressionpredictive factors |
| spellingShingle | Liang Shi Rui Duan Rui Duan Qiong Jia Wenyu Wu Jianming Zhou Shaohua Li Hao Zhang Xue Xue Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer Frontiers in Oncology differentiated thyroid cancer radioiodine indoleamine 2 3-dioxygenase (IDO) immune suppression predictive factors |
| title | Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer |
| title_full | Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer |
| title_fullStr | Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer |
| title_full_unstemmed | Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer |
| title_short | Indoleamine 2,3-Dioxygenase Immune Status as a Potential Biomarker of Radioiodine Efficacy for Advanced Distant Metastatic Differentiated Thyroid Cancer |
| title_sort | indoleamine 2 3 dioxygenase immune status as a potential biomarker of radioiodine efficacy for advanced distant metastatic differentiated thyroid cancer |
| topic | differentiated thyroid cancer radioiodine indoleamine 2 3-dioxygenase (IDO) immune suppression predictive factors |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.871792/full |
| work_keys_str_mv | AT liangshi indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT ruiduan indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT ruiduan indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT qiongjia indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT wenyuwu indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT jianmingzhou indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT shaohuali indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT haozhang indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer AT xuexue indoleamine23dioxygenaseimmunestatusasapotentialbiomarkerofradioiodineefficacyforadvanceddistantmetastaticdifferentiatedthyroidcancer |